

Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021

<https://marketpublishers.com/r/R799322E7D5AEN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: R799322E7D5AEN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Relapsed or Refractory Myelodysplastic Syndrome Understanding

Relapsed or Refractory Myelodysplastic Syndrome: Overview

Myelodysplastic syndromes (MDS) are defined by ineffective hematopoiesis resulting in blood cytopenias, and clonal instability with a risk of clonal evolution to acute myeloid leukemia (AML). Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML3. The goals of therapy for patients with MDS are to reduce disease-associated symptoms and the risk of disease progression and death, thereby improving both quality and quantity of life. Some patients may have no symptoms of disease. MDS may be detected before symptoms appear, as a result of laboratory tests that were part of a routine medical

examination. Treatment for myelodysplastic syndromes includes supportive care, drug therapy, and stem cell transplantation.

“Relapsed or Refractory Myelodysplastic Syndrome- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape is provided which includes the disease overview and Relapsed or Refractory Myelodysplastic Syndrome treatment guidelines. The assessment part of the report embraces, in depth Relapsed or Refractory Myelodysplastic Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed or Refractory Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed or Refractory Myelodysplastic Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Relapsed or Refractory Myelodysplastic Syndrome.

Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs Chapters

This segment of the Relapsed or Refractory Myelodysplastic Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs

CX-01: Cantex Pharmaceuticals

CX-01 is a new chemical entity derived from unfractionated heparin with very low anticoagulant activity. CX-01 targets key protein pathways important for AML blast cell migration to the bone marrow and retention of these cells in the marrow where they are protected from chemotherapy. CX-01 also binds with proteins involved in chemotherapy

resistance and the delay in platelet recovery after chemotherapy. Together, these activities are understood to sensitize AML blasts to chemotherapy and improve clinical responses. These mechanisms of action support the potential for development in myelodysplastic syndrome, multiple myeloma, and lymphomas. Currently in phase 2 of clinical trials for the treatment of Myelodysplastic Syndrome.

LP-108: Newave Pharmaceuticals

Mechanism of Action: Proto-oncogene protein c-bcl-2 inhibitors. The drug is in phase 1 of clinical trials for the treatment of Relapsed or Refractory Myelodysplastic Syndrome

BTX-A51: BioTheryX

BTX-A51 appears to block a specific leukemic stem cell target (CK1-alpha) as well as super enhancer targets (CDK7/CDK9) preventing transcription of key oncogenic genes. BTX-A51 has demonstrated remarkable preclinical animal efficacy implying the eradication of AML stem cells and the potential for use in multiple malignancies. Currently in phase 1 of clinical trials for the treatment of Myelodysplastic Syndrome.

Further product details are provided in the report.....

Relapsed or Refractory Myelodysplastic Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Relapsed or Refractory Myelodysplastic Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Relapsed or Refractory Myelodysplastic Syndrome

There are approx. 5+ key companies which are developing the therapies for Relapsed or Refractory Myelodysplastic Syndrome. The companies which have their Relapsed or Refractory Myelodysplastic Syndrome drug candidates in the mid to advanced stage, i.e. Phase II include, Cantex Pharmaceuticals and others.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Relapsed or Refractory Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Parenteral

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Polymer

Peptide

Gene Therapy

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsed or Refractory Myelodysplastic Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed or Refractory Myelodysplastic Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed or Refractory Myelodysplastic Syndrome drugs.

Relapsed or Refractory Myelodysplastic Syndrome Report Insights

Relapsed or Refractory Myelodysplastic Syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Relapsed or Refractory Myelodysplastic Syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Relapsed or Refractory Myelodysplastic Syndrome drugs?

How many Relapsed or Refractory Myelodysplastic Syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsed or Refractory Myelodysplastic Syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsed or Refractory Myelodysplastic Syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Relapsed or Refractory Myelodysplastic Syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Cantex Pharmaceuticals

Novartis

Newave Pharmaceuticals

BioTheryX

Agios Pharmaceuticals

Key Products

CX-01

BTX-A51

Ruxolitinib

AG-120

LP-108

Contents

Introduction

Executive Summary

Relapsed or Refractory Myelodysplastic Syndrome: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Relapsed or Refractory Myelodysplastic Syndrome – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Relapsed or Refractory Myelodysplastic Syndrome companies' collaborations, Licensing, Acquisition -Deal Value Trends

Relapsed or Refractory Myelodysplastic Syndrome Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

AG-120: Agios Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

CX-01: Cantex Pharmaceuticals

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Early-Stage Products (Phase I)
 Comparative Analysis
BTX A51: BioTheryX
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Relapsed or Refractory Myelodysplastic Syndrome Key Companies
Relapsed or Refractory Myelodysplastic Syndrome Key Products
Relapsed or Refractory Myelodysplastic Syndrome- Unmet Needs
Relapsed or Refractory Myelodysplastic Syndrome- Market Drivers and Barriers
Relapsed or Refractory Myelodysplastic Syndrome- Future Perspectives and
Conclusion
Relapsed or Refractory Myelodysplastic Syndrome Analyst Views
Relapsed or Refractory Myelodysplastic Syndrome Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Relapsed or Refractory Myelodysplastic Syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Relapsed or Refractory Myelodysplastic Syndrome

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/R799322E7D5AEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R799322E7D5AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970